Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Azenta, Inc.AZTA · Entity 4724 | Director | August 08, 2023 | August 09, 2023 |
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | Director | May 07, 2026 | May 11, 2026 |
| GMR Solutions Inc.GMRS · Entity 5222 | Director | August 26, 2026 | August 28, 2026 |
| HAEMONETICS CORPHAE · Entity 3953 | Director | July 24, 2026 | July 28, 2026 |
| Synchrony FinancialSYF · Entity 3184 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Azenta, Inc.
Report date August 08, 2023 · Filed August 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,134 |
Reported balance
After 2023-08-08 transaction · row 1
1 source rowRow 1 · 2023-08-08 · Grant · Disposed 18,766 · Balance 41,134 F1: The sales reported on this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2022.
BOSTON SCIENTIFIC CORP
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,934 |
Reported balance
After 2026-05-07 transaction · row 1
1 source rowRow 1 · 2026-05-07 · Grant · Acquired 3,800 · Balance 27,934 F1: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.
GMR Solutions Inc.
Report date August 26, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 976 |
Reported balance
After 2026-08-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-26 · Grant · Acquired 976 · Balance 976 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer Class A common stock ("Class A Common Stock"). The RSUs will be settled in either Class A Common Stock or cash (or a combination thereof) at the Issuer's discretion. F2: These RSUs vest on the earlier of (i) July 1, 2027 and (ii) the first regularly scheduled annual meeting of the stockholders of the Issuer following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer Class A common stock ("Class A Common Stock"). The RSUs will be settled in either Class A Common Stock or cash (or a combination thereof) at the Issuer's discretion.
F2: These RSUs vest on the earlier of (i) July 1, 2027 and (ii) the first regularly scheduled annual meeting of the stockholders of the Issuer following the date of grant.
HAEMONETICS CORP
Report date July 24, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,911 |
Reported balance
After 2026-07-24 transaction · row 1
1 source rowRow 1 · 2026-07-24 · Grant · Acquired 2,538 · Balance 21,911 F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Synchrony Financial
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,087 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 846 · Balance 33,087 F1: Represents restricted stock units that will vest in full on September 30, 2027. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that will vest in full on September 30, 2027. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PAREXEL INTERNATIONAL CORP
Report date September 29, 2017 · Filed October 04, 2017
Section 16 reporting ended · disclosed 2017-10-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-09-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-09-29 · Disposition to issuer · Disposed 49,534 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the "Merger Consideration"). F2: Ellen Zane holds 22,984 shares of Common Stock directly and 22,550 shares of Common Stock indirectly through a charitable trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the "Merger Consideration").
F2: Ellen Zane holds 22,984 shares of Common Stock directly and 22,550 shares of Common Stock indirectly through a charitable trust.
Press Ganey Holdings, Inc.
Report date October 21, 2016 · Filed October 25, 2016
Section 16 reporting ended · disclosed 2016-10-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-10-21 transaction · row 1
1 source rowRow 1 · 2016-10-21 · Disposition to issuer · Disposed 28,770 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2022 Filed Aug 15, 2022 23:01 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 28 | $36.11 | $1,011.08 |
DisclosureSEC source: 0001601712-22-000219 · wf-form4_166060442728875.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,795 F1 · shares: Represents dividend equivalent units accrued on August 11, 2022 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on August 11, 2022 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 21:44 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-020703 · form4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,247 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:11 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 1,494 | $27.62 | $41,264.28 |
DisclosureSEC source: 0001601712-22-000189 · wf-form4_165705186606953.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,767 F1 · date: Represents restricted stock units that will vest in full on June 30, 2023. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| May 12, 2022 Filed May 16, 2022 20:13 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 24 | $33.03 | $792.72 |
DisclosureSEC source: 0001601712-22-000167 · wf-form4_165273197780305.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,273 F1 · shares: Represents dividend equivalent units accrued on May 12, 2022 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on May 12, 2022 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| May 05, 2022 Filed May 6, 2022 21:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 4,877 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006635 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,683 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:25 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 1,186 | $34.81 | $41,284.66 |
DisclosureSEC source: 0001601712-22-000101 · wf-form4_164910389788238.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,249 F1 · date: Represents restricted stock units that will vest in full on March 31, 2023. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:36 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 17 | $43.66 | $742.22 |
DisclosureSEC source: 0001601712-22-000074 · wf-form4_164556575604988.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,063 F1 · shares: Represents dividend equivalent units accrued on February 17, 2022 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on February 17, 2022 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| February 11, 2022 Filed Jun 9, 2022 21:12 UTC | Azenta, Inc. AZTA · Entity 4724 | GrantCommon Stock | 1,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035464 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,296 F1 · price: Grant of unrestricted shares under the company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:10 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 890 | $46.39 | $41,287.10 |
DisclosureSEC source: 0001601712-22-000011 · wf-form4_164133059274046.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,046 F1 · date: Represents restricted stock units that will vest in full on December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:30 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 15 | $50.18 | $752.70 |
DisclosureSEC source: 0001601712-21-000293 · wf-form4_163709798962926.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,156 F1 · shares: Represents dividend equivalent units accrued on November 12, 2021 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on November 12, 2021 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 20:29 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 844 | $48.88 | $41,254.72 |
DisclosureSEC source: 0001601712-21-000280 · wf-form4_163337935765840.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,141 F1 · date: Represents restricted stock units that will vest in full on September 30, 2022. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:55 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 16 | $51.62 | $825.92 |
DisclosureSEC source: 0001601712-21-000242 · wf-form4_162914732784744.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,297 F1 · shares: Represents dividend equivalent units accrued on August 12, 2021 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on August 12, 2021 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 22:59 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 3,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-023387 · form4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,517 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 13:18 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 696 | $48.52 | $33,769.92 |
DisclosureSEC source: 0001601712-21-000218 · wf-form4_162523190430512.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,281 F1 · date: Represents restricted stock units that will vest in full on June 30, 2022. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| May 13, 2021 Filed May 17, 2021 20:01 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 23 | $45.27 | $1,041.21 |
DisclosureSEC source: 0001601712-21-000184 · wf-form4_162128169671898.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,586 F1 · shares: Represents dividend equivalent units accrued on May 13, 2021 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on May 13, 2021 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| May 06, 2021 Filed May 10, 2021 21:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 4,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007894 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,806 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 20:14 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 831 | $40.66 | $33,788.46 |
DisclosureSEC source: 0001601712-21-000148 · wf-form4_161739441670247.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,563 F1 · date: Represents restricted stock units that will vest in full on March 31, 2022. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:20 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 35 | $37.90 | $1,326.50 |
DisclosureSEC source: 0001601712-21-000090 · wf-form4_161368321108051.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,732 F1 · shares: Represents dividend equivalent units accrued on February 16, 2021 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on February 16, 2021 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 21:13 UTC | Azenta, Inc. BRKS · Entity 4724 | GrantCommon Stock | 1,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008771 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,374 F1 · price: Grant of unrestricted shares under the company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:52 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 973 | $34.71 | $33,772.83 |
DisclosureSEC source: 0001601712-21-000018 · wf-form4_160988352141401.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,697 F1 · date: Represents restricted stock units that will vest in full on December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:12 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 45 | $29.11 | $1,309.95 |
DisclosureSEC source: 0001601712-20-000281 · wf-form4_160556110267420.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,724 F1 · shares: Represents dividend equivalent units accrued on November 12, 2020 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on November 12, 2020 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 21:56 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 1,290 | $26.17 | $33,759.30 |
DisclosureSEC source: 0001601712-20-000243 · wf-form4_160167575269613.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,679 F1 · date: Represents restricted stock units that will vest in full on September 30, 2021. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 20:25 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 50 | $24.70 | $1,235.00 |
DisclosureSEC source: 0001601712-20-000221 · wf-form4_159769589349567.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,389 F1 · shares: Represents dividend equivalent units accrued on August 13, 2020 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on August 13, 2020 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 21:47 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,983 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-021997 · form4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,440 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:23 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 1,524 | $22.16 | $33,771.84 |
DisclosureSEC source: 0001601712-20-000192 · wf-form4_159372135436296.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,339 F1 · date: Represents restricted stock units that will vest in full on June 30, 2021. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:09 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 65 | $17.07 | $1,109.55 |
DisclosureSEC source: 0001601712-20-000161 · wf-form4_158983253468375.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,815 F1 · shares: Represents dividend equivalent units accrued on May 14, 2020 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on May 14, 2020 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007406 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,043 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:30 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 2,098 | $16.09 | $33,756.82 |
DisclosureSEC source: 0001601712-20-000118 · wf-form4_158585941866191.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,750 F1 · date: Represents restricted stock units that will vest in full on March 31, 2021. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:06 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 24 | $33.82 | $811.68 |
DisclosureSEC source: 0001601712-20-000074 · wf-form4_158205995962374.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,652 F1 · shares: Represents dividend equivalent units accrued on February 13, 2020 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on February 13, 2020 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 22:11 UTC | Azenta, Inc. BRKS · Entity 4724 | GrantCommon Stock | 2,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009332 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,614 F1 · price: Grant of unrestricted shares under the company's 2015 Equity Incentive Plan. No amount was paid upon grant of the shares. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:25 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 938 | $36.01 | $33,777.38 |
DisclosureSEC source: 0001601712-20-000017 · wf-form4_157809032638978.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,628 F1 · date: Represents restricted stock units that will vest in full on December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 21:29 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 16 | $36.73 | $587.68 |
DisclosureSEC source: 0001601712-19-000268 · wf-form4_157411257329525.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,690 F1 · shares: Represents dividend equivalent units accrued on November 14, 2019 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on November 14, 2019 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 20:10 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 991 | $34.09 | $33,783.19 |
DisclosureSEC source: 0001601712-19-000226 · wf-form4_157004702354121.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,674 F1 · date: Represents restricted stock units that will vest in full on September 30, 2020. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 21:09 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 11 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001601712-19-000204 · wf-form4_156624892638737.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,683 F1 · shares: Represents dividend equivalent units accrued on August 15, 2019 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on August 15, 2019 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 21:39 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-025272 · form4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,457 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 20:55 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 974 | $34.67 | $33,768.58 |
DisclosureSEC source: 0001601712-19-000169 · wf-form4_156210093747579.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,672 F1 · date: Represents restricted stock units that will vest in full on June 30, 2020. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| May 16, 2019 Filed May 20, 2019 20:07 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 4 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001601712-19-000153 · wf-form4_155838282628082.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698 F1 · shares: Represents dividend equivalent units accrued on May 16, 2019 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on May 16, 2019 as dividends were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| May 09, 2019 Filed May 13, 2019 20:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 4,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-028918 · a4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,043 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 20:08 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 694 | $31.90 | $22,138.60 |
DisclosureSEC source: 0001601712-19-000098 · wf-form4_155423572122817.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 694 F1 · date: Represents restricted stock units that will vest in full on March 31, 2020. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 21:32 UTC | Azenta, Inc. BRKS · Entity 4724 | GrantCommon Stock | 4,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008945 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,783 F1 · price: Grant of unrestricted shares under the company's 2015 Equity Incentive Plan. No amount was paid upon grant of the shares. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 22:25 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-024063 · form4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,997 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 6,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009203 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,053 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 21:16 UTC | Azenta, Inc. BRKS · Entity 4724 | GrantCommon Stock | 3,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008436 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 F1 · price: Grant of restricted shares under the company's 2015 Equity Incentive Plan. All shares vest in one year on the date one day before the Company's 2019 Annual Meeting of Stockholders. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:07 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,301 | $65.86 | $85,683.86 |
DisclosureSEC source: 0001127602-18-002646 · form4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,301 F1 · shares: Restricted Stock Unit grant which vests 100% on the first anniversary of the grant date. The grant was made under the 2005 Long Term Incentive Compensation Plan. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 20:02 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | Disposition to issuerCommon Stock | 49,534 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-023604 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the "Merger Consideration"). F1 · price: Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the "Merger Consideration"). F2 · ownership.direct: Ellen Zane holds 22,984 shares of Common Stock directly and 22,550 shares of Common Stock indirectly through a charitable trust. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 14:09 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | GrantCommon Stock | 1,823 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-027250 · form4.xml · nonDerivative · entry 5 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,984 F1 · security: Shares of restricted stock awarded pursuant to PAREXEL International Corporation 2015 Stock Incentive Plan. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 14:09 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-027250 · form4.xml · nonDerivative · entry 4 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by charitable remainder unitrust Disclosed balance after: 26,550 Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 14:09 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-027250 · form4.xml · nonDerivative · entry 3 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,161 Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 14:09 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | GiftCommon Stock | 9,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-027250 · form4.xml · nonDerivative · entry 2 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by charitable remainder unitrust Disclosed balance after: 24,550 Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 14:09 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | GiftCommon Stock | 9,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-027250 · form4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,161 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.